Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Product Development

What works, what doesn’t and what’s next for COVID-19: Data Byte

A COVID-19 report card and look ahead to the next late-stage readouts

February 19, 2021 1:19 AM UTC

The rise of viral variants underscores the continued need to find new treatments for COVID-19, but so far, most therapeutic candidates have performed far worse in late-stage trials than vaccines.

All the vaccine candidates that have made it through Phase III testing have proven effective, particularly at preventing severe disease. Most therapeutic candidates, by contrast, have failed to benefit patients, and some that have met their endpoints offer modest benefit...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article